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Fludarabine-based therapies are considered to 
be the most adequate and widely applied for treat-
ment of patients with chronic lymphocytic leukemia 
(CLL) [1–4]. However, some patients develop drug 
resistance through variable pathways detectable even 
at diagnosis or more often as the disease progresses 
and acquires drug insusceptibility (relapse, refractory 
disease) [5–6]. In accordance with known molecular 
basis for fludarabine activity (inhibition of DNA repair by 
multiple underlying mechanisms) and chemotherapy 
resistance [7], the application of DNA repair inhibitors 
is among novel strategies to circumvent it, in addition 
to new drug combinations [8].
DNA-dependent protein kinase (DNA-PK) and 
ataxia telangiectasia mutated kinase (ATM)/ATM and 
Rad3 related (ATR) kinases are among key proteins 
required for nonhomologous end joining (NHEJ) and 
homologous recombination pathway. It was demon-
strated that inhibitors of these molecules could be 
applied to overcome the drug and ionizing radiation 
resistance. Besides that it is known that cells, which 
are not sensitive to some drugs, can be sensitized 
by the modifier of multidrug resistance-associated 
protein of ABC family cyclosporin A (CsA), although 
ABC proteins (e.g. P-gp) are not the main nucleoside 
analogue fludarabine transporters in CLL cells [9].
We hypothesized that inhibiting DNA-PK and ATM 
would sensitize CLL cells to drug-induced DNA  damage 
depending on the initial sensitivity to fludarabine. 
Therefore, in the current work we studied the response 
of drug resistant and sensitive CLL cells to fludarabine 
in the presence of the inhibitors known for the above-
mentioned activity with parallel assessment of some 
molecular pathways involved in this interaction.
MATERIALS AND METHODS
Patient samples. Peripheral blood was obtained 
from CLL patients. All patients signed the informed 
consent. Diagnosis was established in compliance with 
the standard clinical and laboratory data according to 
the International Workshop Criteria [10].
Mononuclear cells were separated by density gra-
dient centrifugation. Freshly isolated leukemic cells 
were cultured at a seeding density of 2 x 106 cells/
ml in RPMI-1640 medium supplemented with 2 mM 
L-glutamine, 100 IU/ml penicillin, 100 μg/ml strep-
tomycin and 10% FBS at 37 °C in a humidified atmo-
sphere containing 5% CO2. Cells viability (trypan blue 
exclusion) was > 95%.
Drugs and reagents. Fludarabine (Fludarabel®, 
Belmedpreparaty, Republic of Belarus) was tested in 
the dose of 5 μg/ml that is comparable to the therapeu-
tic drug concentration in blood. Different types of DNA-
PK inhibitors were applied. Small molecule NU7026 
(2-(morpholino-4-yl)-benzo[c]chromen-4-one) and 
less-specific inhibitor vanillin (4-hydroxy-3-meth-
oxybenzaldehyde) were tested for drug sensitization 
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effect. NU7026 was a  generous  gift  from  Dr.  Barbara 
Durkacz (New-Castle upon Tune University, England). 
Caffeine (Tathchimpharmpreparaty, Russia) was used 
as ATM/ATR kinases inhibitor. NU7026 was dissolved 
in anhydrous dimethylsulfoxide, vanillin and caffeine 
were dissolved in distilled water. NU7026 was used in 
all drug combination experiments at final concentra-
tions of 10 μM, vanillin — 200 μM,  caffeine — 7 μM. 
Inhibitors-induced cell death did not exceed 20%. Final 
concentration of MDR protein modulator CsA (Novartis 
Pharmaceutical Corporation, NJ) was 0.5 μM. All other 
reagents were from Sigma (USA), unless otherwise 
stated.
Cytotoxic assay. The cell sensitivity in vitro was 
determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT). Briefly, 
human leukemia cells (2 x 106/ml) were seeded into 
96-well culture plate containing drug(s) and solvent 
controls. After 48 h of incubation 20 μl of MTT solution 
(5 mg/ml in phosphate buffer saline) was added to 
each well, and the cells were incubated for 4 h. The 
formazan crystals were dissolved with 100 μl of acidic 
isopropanol and the absorbance of each well was read 
at 540 nm in a plate reader. Results were expressed as 
a percentage of control. In the case of inhibitor sen-
sitization effect testing, the results were standardized 
in respect to cell viability under inhibitor action alone.
Western blotting. DNA-PKs and ATM expression in 
CLL cells was evaluated using Western blotting. Whole 
cell extracts were prepared and loaded onto Tris-Ace-
tate 3–8% denaturating polyacrylamide gradient gels 
using standard protocols. Samples were transferred 
onto nitrocellulose membrane and probed with antibod-
ies against DNA-PKs, ATM and actin. Anti-mouse HRP-
linked secondary antibodies were used. ECL reagent 
(Amersham, UK) was used for luminescence reaction 
activation. Results quantification was performed with 
a Fuji LAS-3000 luminescent image analyzer system.
Flow cytometric assessment of multidrug 
transporter protein expression and function. P-gp 
expression was analyzed using the protein-specific 
antibody FITC-conjugated anti-P-gp 170 (clone 
17F9) (BD Pharmingen, USA). Protein expression was 
quantitated as percentage of protein positive cells. 
The median fluorescence intensity (MFI) was recorded 
as the median fluorescence channel shift (specific 
antibodies/internal control). MFI was categorized as 
follows: negative (MFI < 1.5) and positive (MFI > 1.5).
Rhodamine 123 was used as substrate for MDR 
protein function assay. CsA modulates the MDR pro-
tein function. Functional activity of MDR proteins was 
estimated as efflux in the presence and absence of 
a modulator: Efflux = [cells with low fluorescence in-
tensity [with modulator] — cells with low fluorescence 
intensity [without modulator] (%). Fluorescence inten-
sity considered to be low when MFI < 1.5.
Assessment of MDR protein gene expression. 
Total RNA extraction was performed using Gen Elute 
Mammalian Total RNA Miniprep Kit according to the 
manufacturer instructions. The quantification and 
A260/A280 ratio were obtained using spectrophotometer 
Gene Quant RNA/DNA Calculator (GE Healthcare). 
Total RNA was also visualized by agarose gel electro-
phoresis. cDNA was synthesized with Advantage RT-
for-PCR Kit (BD, USA) according to the manufacturer 
instructions. As internal control RNA isolated from 
healthy people lymphocytes was used. The variations 
between samples in the quality of RNA extracted and 
subsequent cDNA synthesis were normalized by their 
relative quantities of Gus. IM-9 cell line was used as 
control sample for quantification of studied gene in CLL 
cells. Primers sequences: MDR1 forward primer — 
AGG AAG ACA TGA CCA GGT ATG C, reverse primer: 
CCA ACA TCG TGC ACA TCA AAC, TaqMan: FAM CCT 
GGC AGC TGG AAG ACA AAT ACA CAA BHQ1.
Assessment of pro- and anti-apoptotic genes. 
Apoptosis genes expression on mRNA level was as-
sessed using kit from Maxim Biotech (USA) according 
to the instructions.
Statistical data analysis. Nonparametric sta-
tistics were used, including Spearman rank correla-
tion and the Mann — Whitney test. Statistical data 
were tested for significance by 2-tailed analysis. To 
estimate the modulator sensitization frequency in re-
sistant and sensitive cells we applied χ2 statistics. The 
 re sult  of tests was considered statistically significant 
 if  the  P  ≤  0.05. All statistical analysis was performed 
using the software package Statistica 6.0.
RESULTS
Inhibitors synergy with fludarabine in drug 
resistant CLL cells. Total number of cell samples 
isolated from CLL patients was 115. Variability of cell 
response to drugs alone or in combinations was ob-
served. Sensitization frequency in cells co-treated with 
fludarabine and inhibitors is presented on Fig. 1. The 
overall frequency of sensitized samples increased with 
the decreasing drug sensitivity. According to the fluda-
rabine cell sensitivity in vitro samples were classified 
as sensitive (less than 30% of viable cells, n = 30) and 
resistant (more than 70% of survived CLL lymphocytes, 
n = 21) cases. All other cases (n = 64) had intermediate 
sensitivity (cell viability 30–70%). Caffeine sensitized 
50% of fludarabine-resistant cell samples. DNA-PK 
inhibitors (NU7026 and vanillin) enhanced drug cyto-
toxicity in 27 and 33% resistant samples, respectively, 
and 43% of fludarabine-resistant cell samples were 
sensitized with CsA. At the same time, caffeine and 
CsA were absolutely inactive in fludarabine sensitive 
samples. DNA-PK inhibitors treatment combined with 
fludarabine decreased cell survival in 8 and 16% of 
studied CLL sensitive cases.
DNA-PK and ATM inhibitors sensitized fludarabine-
resistant CLL lymphocytes in 1.2 folds (P < 0.05). 
CsA showed the most pronounced sensitization ef-
fect among drug resistant cells (1.4 folds, P < 0.05). 
However, quantitative sensibilization effect was more 
expressed in drug sensitive CLL cells: 1 out of 5 sen-
sitive CLL samples sensitized with inhibitors showed 
extremely high (100-fold) increase of sensitivity, the 
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other fludarabine sensitive CLL samples were sensi-
tized with inhibitors 3.5-fold on average.
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Fig. 1. Overall sensibilization frequency in cells co-treated with 
fludarabine and inhibitors. CLL cells were treated with fludarabine 
(14 μM) alone or in combination with vanillin (200 μM), caffeine 
(7 μM), NU7026 (10 μM) or CsA (0,5 μM). Each point represents 
average data on 5 to 9 patient samples. Frequency was calcu-
lated as the ratio of sensitized CLL samples number to the total 
number of studied samples in vitro
DNA-PKs level and ATM expression level in CLL 
cells. DNA-PKs level was studied in ex vivo lympho-
cytes from 12 B-CLL patients. DNA-PKs concentra-
tion in ex vivo cell extracts varied 10-fold. However, 
there was not any apparent correlation between the 
DNA-PKs level and fludarabine sensitivity in vitro and 
sensitization effect of DNA-PK inhibitors.
ATM expression was assessed in 10 CLL samples of 
intact malignant lymphocytes. In contrast to DNA-PKs, 
ATM expression level was 2-fold higher in fludarabine 
resistant CLL samples compared with sensitive ones 
(P < 0.05) (Fig. 2).
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Fig. 2. ATM and DNA-PK expression in fludarabine sensitive (S) 
and resistant (R) CLL samples. DNA-PKs and ATM expression 
in CLL cells was evaluated by Western blotting. Membranes 
were probed with antibodies against DNA-PKs, ATM and actin. 
Anti-mouse HRP-linked secondary antibodies were used. ECL 
reagent was used for luminescence reaction activation. Results 
quantification was performed with a Fuji LAS-3000 luminescent 
image analyzer system
Fludarabine sensitivity of CLL cells in respect 
to MDR protein expression and function. As the 
percentage of P-gp positive cells was unreliable pa-
rameter because of P-gp trace amount, we used MFI 
and Kolmogorov-Smirnov D statistics. MFI median did 
not reveal any difference in drug sensitive and resistant 
cells. Rhodamine 123 efflux features the intensity of 
P-gp function. Intensification of P-gp function was 
shown in drug sensitive cells compared with resistant 
subset (Table 1). More pronounced suppression of 
MDR protein function by CsA was shown in fludarabine 
sensitive CLL subset.
Table 1. MDR protein/gene expression and function in CLL cells with dif-
ferent response to fludarabine ex vivo
MDR status parameters
CLL lymphocytes response to fluda-
rabine ex vivo p
drug sensitive drug resistant
P-gp positive cells.% 0.72 (0.34–0.80) 0.25 (0.19–1.93) 0.56
P-gp MFI. a.u. 1.88 (1.67–3.31) 2.06 (1.52–2.47) 0.29
P-gp efflux: number of cells 
with weak fluorescent dye ac-
cumulation.%
51 (37–74) 28 (23–39) * 0.04
The extent of CsA suppression 
of MDR proteins activity. fold
2.76 (2.06–3.77) 1.63 (1.58–1.68)* 0.04
Note: * p <0.05.
Expression of mRNA of molecules involved in 
apoptosis in CLL cells. No difference in mRNA ex-
pression levels was found between fludarabine resis-
tant and sensitive CLL lymphocytes for pro-apoptotic 
genes TRAIL, FAS, FLICE and for anti-apoptotic genes 
BCL-2 and BCL-XL. However, mRNA level of pro-
apoptotic BCL-XS was increased in sensitive samples 
(Table 2, Fig. 3).
Table 2. Apoptosis gene mRNA quantification in fludarabine-sensitive and 
fludarabine-resistant CLL subsets
Apoptosis gene
The relative intensity of mRNA expression in
fludarabine sensitive 
CLL lymphocytes
fludarabine resistant 
CLL lymphocytes
Mitochondrial apoptosis pathway
BCL-XL 0.26 (0.25–0.33) 0.22 (0.13–0.30)
BCL-2 0.45 (0.44–0.52) 0.44 (0.41–0.61)
BCL-XS 0.15 (0.15–0.16) 0.07 (0.06–0.12)*
LICE 0.08 (0.06–0.34) 0.19 (0.19–0.20)
Receptor-induced apoptosis pathway
FLICE 0.72 (0.42–0.99) 0.67 (0.62–0.79)
FAS 0.23 (0–0.45) 0.03 (0 — 0.1)
TRAIL 0.06 (0–0.10) 0.20 (0.11–0.38)
Note: * p <0.01.
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Fig. 3. Pro- and anti-apoptotic mRNA gene expression in 
fludarabine sensitive (S) and resistant (R) CLL samples. Multi-
plex polymerase chain reaction was used for genes expression 
analysis. It was assessed with kit from Maxim Biotech. Expression 
of GAPDH gene was used as control
Furthermore, mRNA of pro-apoptotic genes was 
investigated in CLL samples in connection with dif-
ferent response to inhibitors: cells sensitized to fluda-
rabine by all studied inhibitors and CLL lymphocytes 
unresponsive to the inhibitors. Not sensitized cells 
from fludarabine-resistant and sensitive samples had 
elevated expression levels of BAX and LICE (procas-
pase 3) mRNA and decreased mRNA level of pro-
apoptotic agent BCL-XS and anti-apoptotic BCL-XL. 
No difference in mRNA expression of FAS, FASL, 
TRAIL, FLICE genes was shown between sensitized 
and not sensitized CLL subgroups.
DISCUSSION
Fludarabine cytotoxicity is mediated by the DNA 
synthesis and repair inhibition. In the current work we 
hypothesized that repair of DNA damage induced by 
fludarabine may be mediated in part via DNA-PK, ATM 
and probably via MDR. Therefore DNA-PK, ATM and may 
be MDR inhibitors would sensitize cells to this agent.
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Taking into account that ATR activity is downregu-
lated in non-cycling CLL cells, we consider that caffeine 
as ATM inhibitor sensitized CLL cells to fludarabine 
most frequently (50% of resistant samples). DNA-PK 
inhibitors vanillin and NU7026 sensitized resistant 
lymphocytes in 27 and 33% of samples, respectively. 
CsA increased fludarabine cytotoxicity in 43% of re-
sistant samples. Fludarabine activity in drug sensitive 
CLL lymphocytes was enhanced by caffeine and CsA 
not more than in 16 and 8%, respectively. But DNA-PK 
inhibitors were entirely inactive in CLL cells responded 
to fludarabine. However, small number of fludarabine 
sensitive samples (5 out of 30) that were able to respond 
to inhibitors were sensitized with them to a greater 
extent than initially fludarabine resistant CLL samples.
Previously, it was demonstrated that fludarabine 
activity was potentiated in the presence of DNA-PK 
inhibitor NU7441 by 2–14 folds, while in our study 
potentiating effect depended on the initial fludarabine 
sensitivity and varied greatly from 1.1 to more than 
100 fold. Sensitization effect of NU7441 was shown in 
73% of studied cases [11], though our study established 
response dependence on initial drug sensitivity rate.
We didn’t demonstrate any correlation between 
DNA-PKs expression and fludarabine sensitivity, and 
inhibitor sensitization. However, increased ATM level 
was detected in fludarabine-resistant cells. In other 
studies it was shown that DNA-PKs levels correlated 
with DNA-PK activity though varied 50-fold between 
cases. NU7441 sensitized CLL cells to chlorambucil 
and fludarabine, and abrogated drug-induced auto-
phosphorylation of DNA-PKs at Ser2056. In addition, 
high DNA-PK levels were even predictive for reduced 
treatment-free interval [12]. Moreover, human fibro-
 blasts pretreated with DNA-PKs inhibitors vanillin and 
Wortmannin showed increased levels of chromosome 
breakages and became more sensitive to fludarabine-
induced cell death. An active role of NHEJ pathway was 
also suggested from the analysis of Chinese hamster 
cell lines. XR-C1 (DNA-PKs-deficient) and XR-V15B 
(Ku80-deficient) cells showed hypersensitivity to fluda-
rabine as was detected by the increased frequency of 
chromosome aberrations, decreased mitotic index 
and impaired survival rates [13]. At the same time, no 
significant induction of homologous recombination after 
fludarabine treatment was shown. Taken together these 
data and our results underlined the heterogeneity of 
studied molecular properties of leukemia cells in CLL 
patients and the necessity of development of differenti-
ated treatment approach in future.
It is known that MDR proteins expression could be 
one of the reasons for drug resistance development. 
Some data evidence that fludarabine has capacity to 
overcome the negative effect of MDR overexpression. 
Therefore, response to fludarabine doesn’t correlate 
with P-gp status. These data support our findings con-
cerning decreased P-gp function and its impaired CsA 
suppression in fludarabine resistant CLL cells. Moreover, 
it is necessary to take into consideration equilibrative and 
concentrative nucleoside transporter (ENT, CNT) family 
as far as fludarabine accumulation in CLL cells is mostly 
mediated by ENT and hCNT3 type transporters. Their 
biologic activity was clearly correlated with fludarabine 
cytotoxicity. It reveals a role of ENT-mediated uptake in 
drug responsiveness in patients with CLL [14, 15].
As fludarabine may induce apoptosis in a CD95/
Fas receptor, FADD, IAPs and caspase-8-independent 
manner by activation of the mitochondrial cell death 
pathway [16, 17], our results concerning FAS and 
TRAIL mRNA content in CLL lymphocytes with different 
fludarabine sensitivity could be in line with these data.
The role of BCL-2, BAX, BAG-1, and MCL-1 pro-
teins in CD5/CD20-positive B-CLL cells has already 
been elucidated. BCL-2 expression was decreased 
after fludarabine treatment. MCL-1 expression was 
increased in fludarabine-resistant cells and seemed 
to be a remarkable protein for the inhibition of the 
apoptotic process in CLL. After fludarabine treatment, 
 BAG-1 expression was increased in fludarabine-
resistant cells [18]. Though the apoptotic program 
induction depends on the subtle mitochondrial protein 
balance, BCL-XS was the only gene in our study that 
showed the difference in fludarabine resistant and 
sensitive cells. Cells non-sensitized with DNA-PK and 
ATM inhibitors had elevated expression of BAX and 
LICE (procaspase 3) mRNA and decreased mRNA 
level of pro-apoptotic BCL-XS and anti-apoptotic 
BCL-XL mRNA.
According to our data drug cell response ex vivo is an 
integral test for cellular molecular biological properties 
defining the treatment course outcome [19]. However, 
exact underlying mechanisms of drug resistance are 
still obscure, and have some peculiarities in individual 
patients. In this connection the idea of new approaches 
to overcoming drug resistance on the basis of evaluation 
of differentiated resistant and sensitive cell responses 
to variable agents should not be neglected.
Unfortunately, molecular profiling of leukemia cells 
does not always correlate with their drug sensitivity, 
and cannot give ultimate predictive answer for treat-
ment choice. These data validate the known concept 
of targeting DNA repair mechanisms in therapy. There-
fore, the novel observation that fludarabine-resistant 
cells may be susceptible to the action of DNA repair 
inhibitors more often than fludarabine-sensitive cells, 
could be of experimental and, in future, of certain 
clinical significance. At least, our in vivo studies of CLL 
patients’ early response to fludarabine-based therapy 
demonstrated that vanillin in vitro was more often ac-
tive in cells obtained from early non-responders com-
pared with cells from early responders though cells of 
in vivo responders were more sensitive to fludarabine 
in vitro [20]. 
As a whole, in the current work variable associa-
tion between studied genes expression in CLL cells 
and fludarabine sensitivity was demonstrated. Pos-
sibly additional investigations of inhibitors activity 
may clarify the situation. Anyway, this fact does not 
cancel inhibitors’ synergy with fludarabine in drug 
resistant lymphoid cells that can be used to overcome 
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resistance to nucleoside analogs in treatment of 
lymphoid malignancies. Evidently, the usage of more 
individual approach to standard regimens is needed 
at the present moment. Therefore, direct evaluation 
of cellular fludarabine sensitivity and its modulation by 
variable stimulators and inhibitors of different signal-
ing pathways may be more preferable than estimation 
of expression of genes and proteins known for their 
predictive significance.
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